Insulet's Net Loss Widens, But Revenue Improves
Once these most recent quarterly results are finalized, they will be run through TheStreet.com Ratings' model and our ratings will be adjusted accordingly. To keep up to date on all of our ratings, visit TheStreet.com Ratings Screener.
On March 5, 2009, Insulet (PODD), a medical device maker, reported that its Q4 FY08 net loss widened, hurt by a restructuring charge and higher expenses. Net loss stood at $28.28 million, or $1.02 per share, compared to a loss of $15.67 million, or $0.59 per share, in Q4 FY07. Net loss was negatively impacted by a restructuring charge of $8.20 million related to the transition of the company's manufacturing activities to China. The most recent consensus estimate was for a loss of $0.64 per share.
Insulet's revenue surged 172.0% to $11.86 million from $4.36 million in the prior year's quarter. The company improved to a gross profit of 10.10% from a gross loss of 53.15% in the prior year's quarter, as revenue outpaced the cost of revenue, which increased 59.6% to $10.66 million from $6.68 million.
During the quarter under review, research and development expenses spiked 11.5% to $3.54 million from $3.17 million. General and administrative costs increased 34.9% to $6.85 million from $5.08 million. Sales and marketing costs surged 82.2% to $10.00 million from $5.49 million in the year-ago quarter. Operating expenses swelled 107.9% to $28.55 million from $13.74 million, due to the expansion of the company's sales organization and infrastructure and a restructuring charge. PODD recently announced the appointment of Brian Roberts as chief financial officer. For FY08, net loss widened to $92.79 million, or $3.36 per share, from a loss of $53.54 million, or $3.21 per share, in FY07. Annual revenue soared 169.7% to $36.06 million from $13.37 million a year ago. Looking forward to 2009, Insulet estimates revenue to be in the range of $55.00 to $65.00 million. The company also expects its operating loss to be in the range of $50.00 to $60.00 million.Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Dividend Stock Advisor
TRY IT FREENew! $49.95/yr
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Real Money
TRY IT FREE24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
Product Features:
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
